Trials / Conditions / t(8;21)
t(8;21)
3 registered clinical trials studyying t(8;21) — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Enrolling By Invitation | Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) NCT06499025 | BGI, China | EARLY_Phase 1 |
| Withdrawn | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation NCT03560908 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Tre NCT00801489 | M.D. Anderson Cancer Center | Phase 2 |